SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York.
Nautilus management is scheduled to participate in a fireside chat on Wednesday, September 4, 2024, at 7:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
New report identifies benefits and concerns regarding telehealth, provides recommendations for improving perceptions DENVER, Aug. 14,…
Assisted clinical documentation tool from Abridge helps doctors reduce time spent on administrative tasks, allowing…
Dig into the pet sector's hardest-hitting topics with Barking Mad, available on all leading podcast…
Brain-CA Technologies has secured patents for a new AI solution based on Cellular Automata that…
ALPHARETTA, Ga., Aug. 14, 2024 /PRNewswire/ -- Medicus IT ("Medicus" or "the Company"), the leading…
SANTA BARBRA, Calif. , Aug. 14, 2024 /PRNewswire/ -- Know Yourself, founded by Nancy Howes and Tim…